Pharmaceutical Care Management Association (PCMA)’s Post

#PCMA along with #Caremark, #OptumRx, #expressscripts,#ESI, #CVS, #Optum have been stealing from the American people and this has been known for a very long time!!! The FTC and legislators previously sanctioned the PCMA and vertically-integrated PBMs greedy anti-competitive policies that have allowed this dire situation the American people live in today! Slow paced action or nearly inaction as we have seen by the FTC and legislators is just giving the greedy executives time to eliminate any competition and steal every last possible dollar from the American people, non-vertically integrated pharmacies and employers. #stopthesiphon PCMA and the Big 3 PBMs are ONLY in this for the money and they could care less about the patients and the wasteland they leave. The proof is in the pudding!!!

A successful market access strategy is pivotal for pharmaceutical brands to reach patients by navigating coverage and reimbursement challenges. Check out our latest POV that highlights how to avoid common pitfalls with a smart market access strategy for brand success. https://ow.ly/FUSL50RssS7

The Pharmaceutical Care Management Association (PCMA) released the following statement on the inclusion of substantial, misguided policies targeting prescription drug benefits, in both Medicare and the commercial marketplace, in the text of a proposed government funding package. https://lnkd.in/eiv9E9xY

Great to see the new Repeat Prescribing Toolkit published today: https://lnkd.in/epWdnpMk This is the result of a collaborative effort across multiple organisations and groups with top leadership from Clare Howard and Clare Thomson 👏🏽 There are a number of ways repeat prescribing can be managed more effectively and safely. Here are a few top tips: 🛒Minimise the number of ways patients request repeat prescriptions to fewer streamlined methods. Adopting digital methods such as the NHS App should be prioritised whilst ensuring availability of inclusive options for those requiring non-digital routes. ✒️ Ensure practice workflow needs are met through optimising use of prescribing IT systems. E.g. bulk signing - solutions should maximise efficiency without introducing patient safety /overprescribing risks. 📖 Encourage patients to attend their medication review appointments through education and awareness. A 'Me & My Medicines' patient information campaign targeting BAME groups was trialled by HI East Midlands and shown to double SMR appointment attendances. 💊 Use practice and community pharmacy staff to help with deprescribing, repeat prescription management, identifying high risk polypharmacy patients, and conducting medication use reviews. Royal Pharmaceutical Society RCGP

We have rebated $42.8 Billion dollars to your insurance entities last year. $13.4 to private insurance alone. How much of that have you seen in savings? That's $40 PER PERSON in the US, much more for the individual receiving the products likely over $500 per person. Healthcare overall needs to address this where you are more likely to get access to a therapy based on how much your insurance makes in reimbursement over a therapy that will work for you.

Here's my latest guest column with The Evidence Base® capturing value highlights from March and April.

Kimberly Westrich (Chief Strategy Officer, National Pharmaceutical Council) shares her highlights in US healthcare value and access from July and August 2024. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #hta #healthtechnologyassessment #healthdata #healthpolicy #valueassessment #inflationreductionact

What are the top 5 reasons why NICE submissions are unsuccessful? And how can you avoid them? Our Senior HTA Manager, Tomas Keating answers these questions and adds his insights on what makes for a successful submission. NICE conducts Health Technology Assessments (HTAs) on pharmaceutical products in England, assessing cost-effectiveness to endorse treatments for NHS patients. Our blog on this topic includes real-world case studies across therapy areas. You can read the full blog here: https://lnkd.in/eznk2WgR #NICE #HealthTechnologyAssessment #NHS

This report by Adam Fein offers valuable insights into the complexities of drug pricing and the gross-to-net bubble within the pharmaceutical industry. #pharma #drugpricing #healthcareeconomics

Kimberly Westrich (Chief Strategy Officer, National Pharmaceutical Council) shares her highlights in US healthcare value and access from March and April 2024. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #hta #healthtechnologyassessment #healthdata #ISPORAnnual